![Simon Ward](https://profiles-cardiff.imgix.net/attachments/3674?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Yr Athro Simon Ward
- Siarad Cymraeg
- Ar gael fel goruchwyliwr ôl-raddedig
Timau a rolau for Simon Ward
Cyfarwyddwr, Sefydliad Darganfod Meddyginiaethau
Trosolwyg
Mae'r Athro Simon Ward yn Athro Darganfod Cyffuriau Trosiadol Sêr Cymru, a Chyfarwyddwr y Sefydliad Darganfod Meddyginiaethau ym Mhrifysgol Caerdydd. Nod y sefydliad, sy'n fuddsoddiad pwysig mewn gwyddoniaeth darganfod cyffuriau, yw cyfieithu dealltwriaeth newydd o fecanweithiau clefydau yng Nghaerdydd, Cymru a rhyngwladol i ddatblygu dulliau therapiwtig newydd ar gyfer cleifion sydd angen gwell opsiynau triniaeth.
Mae'r Athro Simon Ward yn arbenigwr blaenllaw byd-eang mewn cemeg feddyginiaethol, darganfod cyffuriau a datblygu cyffuriau ac mae wedi gyrru sawl prosiect o gysyniad i astudiaethau clinigol canol cam ar gyfer ystod o glefydau. Mae ganddo brofiad helaeth ar draws sectorau o gwmnïau fferyllol mawr, cwmnïau biotechnoleg, elusennau a'r byd academaidd, yn ogystal â phrofiad arbenigol o ddarganfod a datblygu cyffuriau ar gyfer cleifion ag anhwylderau niwrolegol a seiciatrig ac yn erbyn canser. Mae ganddo brofiad sylweddol o fargeinion trwyddedu llwyddiannus, diwydrwydd dyladwy, ymgyfreitha patent a chreu cytundebau masnachol.
Cyhoeddiad
2025
- Reeks, J. et al. 2025. High throughput cryo-EM provides structural understanding for modulators of the lysosomal ion channel TRPML1. Structure (10.1016/j.str.2025.05.014)
- Baldwin, A. G. et al. 2025. Discovery of MDI-114215: A potent and selective LIMK inhibitor to treat fragile X syndrome. Journal of Medicinal Chemistry 68(1), pp. 719-752. (10.1021/acs.jmedchem.4c02694)
- Baldwin, A. et al. 2025. Discovery of MDI-114215: A potent and selective LIMK inhibitor to treat Fragile X Syndrome. Journal of Medicinal Chemistry 68(1), pp. 719-752. (10.1021/acs.jmedchem.4c02694)
- Nicholls, R. A. et al. 2025. How do gepotidacin and zoliflodacin stabilize DNA-cleavage complexes with bacterial type IIA topoisomerases? 2. A single moving metal mechanism. International Journal of Molecular Sciences 26(1), article number: 33. (10.3390/ijms26010033)
2024
- Cubitt, J. et al. 2024. Beware of N-Benzoyloxybenzamides. Molecules 29(21), article number: 5143. (10.3390/molecules29215143)
- Morgan, H. et al. 2024. How do Gepotidacin and Zoliflodacin stabilize DNA cleavage complexes with bacterial Type IIA topoisomerases? 1. Experimental definition of metal binding sites. International Journal of Molecular Sciences 25(21), article number: 11688. (10.3390/ijms252111688)
- Henderson, S. et al. 2024. Imidazo[1,2-b]pyridazines as inhibitors of DYRK kinases. European Journal of Medicinal Chemistry 269, article number: 16292. (10.1016/j.ejmech.2024.116292)
2023
- Zhou, J. et al. 2023. Myeloid-intrinsic cell cycle-related kinase drives immunosuppression to promote tumorigenesis. iScience 26(10), article number: 107626. (10.1016/j.isci.2023.107626)
- Derudas, M. et al. 2023. Charge and lipophilicity are required for effective block of the hair-cell mechano-electrical transducer channel by FM1-43 and its derivatives. Frontiers in Cell and Developmental Biology 11, article number: 1247324. (10.3389/fcell.2023.1247324)
- Thomas, B., Lewis, L., Jones, D. and Ward, S. 2023. Central nervous system targeted protein degraders. Biomolecules 13(8), article number: 1164. (10.3390/biom13081164)
- Ward, S. E. and Davis, A. M. 2023. Lead optimisation: what you should know!. In: Ward, S. E. and Davis, A. eds. The Handbook of Medicinal Chemistry: Principles and Practice. The Royal Society of Chemistry, pp. 720-768., (10.1039/9781788018982-00720)
2022
- Ward, S. et al. 2022. Heteroaryl compounds useful in the treatment of cognitive disorders. WO2022/234271 [Patent].
- Collins, R. et al. 2022. Comparative analysis of small-molecule limk1/2 inhibitors: chemical synthesis, biochemistry, and cellular activity. Journal of Medicinal Chemistry (10.1021/acs.jmedchem.2c00751)
- Koulouris, C. R. et al. 2022. Tyrosine 121 moves revealing a ligandable pocket that couples catalysis to ATP-binding in serine racemase. Communications Biology 5(1), article number: 346. (10.1038/s42003-022-03264-5)
- Scott, F. et al. 2022. Development of dihydropyrrolopyridinone-based PKN2/PRK2 chemical tools to enable drug discovery. Bioorganic and Medicinal Chemistry Letters 60, article number: 128588. (10.1016/j.bmcl.2022.128588)
2021
- Henderson, S. H. et al. 2021. Discovery and characterization of selective and ligand-efficient DYRK inhibitors. Journal of Medicinal Chemistry 64(15), pp. 11709–11728. (10.1021/acs.jmedchem.1c01115)
- Zeng, X., Ward, S. E., Zhou, J. and Cheng, A. S. L. 2021. Liver immune microenvironment and metastasis from colorectal cancer-pathogenesis and therapeutic perspectives. Cancers 13(10), article number: 2418. (10.3390/cancers13102418)
- Kenyon, E. J. et al. 2021. Identification of a series of hair-cell MET channel blockers that protect against aminoglycoside-induced ototoxicity. JCI Insight 6(7), article number: e145704. (10.1172/jci.insight.145704)
- Cockerill, G. S. et al. 2021. Discovery of sisunatovir (RV521), an inhibitor of respiratory syncytial virus fusion. Journal of Medicinal Chemistry 64(7), pp. 3658-3676. (10.1021/acs.jmedchem.0c01882)
- Chen, X. et al. 2021. Uncovering an allosteric mode of action for a selective inhibitor of human Bloom syndrome protein. eLife 10, article number: e65339. (10.7554/eLife.65339)
2020
- Henderson, S. H. et al. 2020. Mining public domain data to develop selective DYRK1A inhibitors. ACS Medicinal Chemistry Letters 11, pp. 1620-1626. (10.1021/acsmedchemlett.0c00279)
- Milton-Harris, L., Jeeves, M., Walker, S. A., Ward, S. E. and Mancini, E. J. 2020. Small molecule inhibits T-cell acute lymphoblastic leukaemia oncogenic interaction through conformational modulation of LMO2. Oncotarget 11(19), pp. 1737-1748. (10.18632/oncotarget.27580)
- Scott, F., Fala, A. M., Pennicott, L. E., Reuillon, T. D., Massirer, K. B., Elkins, J. M. and Ward, S. E. 2020. Development of 2-(4-pyridyl)-benzimidazoles as PKN2 chemical tools to probe cancer. Bioorganic and Medicinal Chemistry Letters 30(8), article number: 127040. (10.1016/j.bmcl.2020.127040)
- Maramai, S., Benchekroun, M., Ward, S. E. and Atack, J. R. 2020. Subtype selective y-Aminobutyric acid type A receptor (GABAAR) modulators acting at the benzodiazepine binding site: An update. Journal of Medicinal Chemistry 63(7), pp. 3425-3446. (10.1021/acs.jmedchem.9b01312)
- Ward, S. E. et al. 2020. Pharmacological characterisation of MDI-222, a novel AMPA receptor positive allosteric modulator with an improved safety profile. Journal of Psychopharmacology 34(1), pp. 93-102. (10.1177/0269881119872198)
2019
- O'Reilly, M. et al. 2019. Design, synthesis, and biological evaluation of a new series of carvedilol derivatives that protect sensory hair cells from aminoglycoside-induced damage by blocking the mechanoelectrical transducer channel. Journal of Medicinal Chemistry 62(11), pp. 5312-5329. (10.1021/acs.jmedchem.8b01325)
2018
- Mok, M. S., Zhou, J., Tang, W., Zeng, X., Oliver, A., Ward, S. and Cheng, A. S. 2018. CCRK is a novel signalling hub exploitable in cancer immunotherapy. Pharmacology & Therapeutics 186, pp. 138-151. (10.1016/j.pharmthera.2018.01.008)
- Henderson, S. H., West, R. A., Ward, S. E. and Honey, M. A. 2018. Metal-free selective mono-halodecarboxylation of heteroarenes under mild conditions. Royal Society Open Science 5(6), article number: 180333. (10.1098/rsos.180333)
- West, R. A., Cunningham, T., Pennicott, L. E., Rao, S. P. S. and Ward, S. 2018. Toward more drug like inhibitors of trypanosome alternative oxidase. ACS Infectious Diseases 4(4), pp. 592-604., article number: 7b00218. (10.1021/acsinfecdis.7b00218)
2017
- Kenyon, E. J. et al. 2017. Identification of ion-channel modulators that protect against aminoglycoside-induced hair cell death. JCI Insight 2(24), article number: e96773. (10.1172/jci.insight.96773)
- West, R. A. et al. 2017. African trypanosomiasis: Synthesis & SAR enabling novel drug discovery of ubiquinol mimics for trypanosome alternative oxidase. European Journal of Medicinal Chemistry 141, pp. 676-689. (10.1016/j.ejmech.2017.09.067)
- Kirkwood, N. K. et al. 2017. d-Tubocurarine and berbamine: alkaloids that are permeant blockers of the hair cell's mechano-electrical transducer channel and protect from aminoglycoside toxicity. Frontiers in Cellular Neuroscience 11, article number: 262. (10.3389/fncel.2017.00262)
- Ward, S. et al. 2017. Pharmacological characterization of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2, 3-dihydro-1H-inden-2-yl]-2-propanesulfonamide: a novel, clinical AMPA receptor positive allosteric modulator. British Journal of Pharmacology 174(5), pp. 370-385. (10.1111/bph.13696)
- Meisenberg, C. et al. 2017. Epigenetic changes in histone acetylation underpin resistance to the topoisomerase I inhibitor irinotecan. Nucleic Acids Research 45(3), pp. 1159-1176. (10.1093/nar/gkw1026)
2016
- Phuangsawai, O. et al. 2016. Evaluation of the anti-malarial activity and cytotoxicity of 2,4-diamino-pyrimidine-based kinase inhibitors. European Journal of Medicinal Chemistry 124, pp. 896-905. (10.1016/j.ejmech.2016.08.055)
- Ocasio, C. A. et al. 2016. A first generation inhibitor of human Greatwall kinase, enabled by structural and functional characterisation of a minimal kinase domain construct. Oncotarget 7(44), pp. 71182-71197. (10.18632/oncotarget.11511)
- Hornyak, P. et al. 2016. Mode of action of DNA-competitive small molecule inhibitors of tyrosyl DNA phosphodiesterase 2. Biochemical Journal 473(13), pp. 1869-1879. (10.1042/BCJ20160180)
- Cockerill, S., Mathews, N., Ward, S., Lunn, G., Paradowski, M. and Gascon Simorte, J. M. 2016. Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (RSV). WO2016055780A1 [Patent].
- Moore, T. O., Paradowski, M. and Ward, S. 2016. An atom-efficient and convergent approach to the preparation of NS5A inhibitors by C-H activation. Organic and Biomolecular Chemistry 14(12), pp. 3307-3313. (10.1039/C6OB00340K)
- Schindler, R. et al. 2016. Pyrazoles as NMDA NR2B receptor inhibitors and their preparation. WO2016025918A1 [Patent].
- Schindler, R., Lankau, H., Hofgen, N., Egerland, U., Langen, B., Dost, R. and Ward, S. 2016. Triazoles as nr2b receptor inhibitors. WO2016025917A1 [Patent].
- Reuillon, T., Ward, S. and Beswick, P. 2016. AMPA receptor positive allosteric modulators: Potential for the treatment of neuropsychiatric and neurological disorders. Current Topics in Medicinal Chemistry 16(29), pp. 3536-3565. (10.2174/1568026616666160627114507)
- Ward, S., Dawson, L. A., Konneh, M. and MacDonald, G. 2016. Alzheimer's disease therapeutics - Are we making progress towards a disease-modifying treatment for patients? Highlights from the Society for Medicines Research Symposium, held June 20, 2016. Presented at: Society for Medicines Research Symposium, 20th June 2016, Vol. 41. Vol. 7. Prous Science pp. 461., (10.1358/dof.2016.041.07.2516439)
2015
- Ward, S., Pennicott, L. E. and Beswick, P. 2015. AMPA receptor-positive allosteric modulators for the treatment of schizophrenia: an overview of recent patent applications. Future Medicinal Chemistry 7(4), pp. 473-491. (10.4155/fmc.15.4)
- Pearl, L. H., Schierz, A. C., Ward, S., Al-Lazikani, B. and Pearl, F. M. G. 2015. Therapeutic opportunities within the DNA damage response. Nature Reviews Cancer 15(3), pp. 166-180. (10.1038/nrc3891)
- Brown, K., Davenport, R. and Ward, S. 2015. Effective and emerging strategies for utilizing structure in drug discovery. Presented at: Society for Medicines Research Meeting, 19th March 2015, Vol. 40. Vol. 4. Prous Science pp. 251-256., (10.1358/dof.2015.040.04.2314768)
2014
- Meisenberg, C., Gilbert, D. C., Chalmers, A., Haley, V., Gollins, S., Ward, S. and El-Khamisy, S. F. 2014. Clinical and cellular Roles for TDP1 and TOP1 in modulating colorectal cancer response to irinotecan. Molecular Cancer Therapeutics 14(2), pp. 575-585. (10.1158/1535-7163.MCT-14-0762)
- Meisenberg, C., Ward, S., Schmid, P. and El-Khamisy, S. F. 2014. TDP1/TOP1 Ratio as a Promising Indicator for the Response of Small Cell Lung Cancer to Topotecan. Journal of Cancer Science & Therapy 6(7), pp. 258-267. (10.4172/1948-5956.1000280)
- Ward, S. and Beswick, P. 2014. What does the aromatic ring number mean for drug design?. Expert Opinion on Drug Discovery 9(9), pp. 995-1003. (10.1517/17460441.2014.932346)
- Walker, S. et al. 2014. Development of an oligonucleotide-based fluorescence assay for the identification of tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors. Analytical Biochemistry 454, pp. 17-22. (10.1016/j.ab.2014.03.004)
2013
- Gibbs, A. A., Ward, S. and Pennicott, L. E. 2013. Neurodevelopmental disorders. WO 2013/038200 A2 [Patent].
- Ward, S. 2013. Targets and emerging therapies for schizophrenia. Edited by Jeffrey S. Albert and Michael W. Wood [Book Review]. ChemMedChem 8(3), pp. 529. (10.1002/cmdc.201200589)
2012
- Andreotti, D., Norton, D., Price, H. S., Profeta, R., Spada, S. and Ward, S. 2012. Piperazine derivatives as cav2.2 calcium channel blockers. WO2012098400A1 [Patent].
- Bertheleme, N., Beswick, P. J., Gleave, R. J., Hachisu, S., Vile, S. and Ward, S. 2012. Tetrazole compounds as calcium channel blockers. WO2012004604A1 [Patent].
2011
- Ward, S. et al. 2011. Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators. Journal of Medicinal Chemistry 54(1), pp. 78-94. (10.1021/jm100679e)
- Davenport, R., Armour, R. and Ward, S. 2011. Trends in pain research. Presented at: The Society for Medicines Research Pain Meeting, Girton College, Cambridge, UK, 24 March 2011, Vol. 36. Vol. 12. Prous Science pp. 943-948., (10.1358/dof.2011.036.12.1738058)
- Cowley, P., Hales, N. and Ward, S. 2011. Trends in medicinal chemistry. Presented at: The Society For Medicines Resarch Symposiun, NHLI, London, UK, 9 December 2010, Vol. 36. Vol. 7. Prous Science pp. 543-549., (10.1358/dof.2011.036.07.1622065)
2010
- Leslie, C. P. et al. 2010. Discovery of 1-(3-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a potent, selective, and orally active 5-HT1A/B/DReceptor antagonist. Journal of Medicinal Chemistry 53(23), pp. 8228-8240. (10.1021/jm100714c)
- Thewlis, K. M., Aldegheri, L., Harries, M. H., Mookherjee, C., Oliosi, B. and Ward, S. 2010. N-Substituted pyrrolidines and tetrahydrofurans as novel AMPAR positive modulators. Bioorganic & Medicinal Chemistry Letters 20(23), pp. 7116-7119. (10.1016/j.bmcl.2010.09.062)
- Ward, S. et al. 2010. Discovery of N-[(2S)-5-(6-Fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator. Journal of Medicinal Chemistry 53(15), pp. 5801-5812. (10.1021/jm1005429)
- Bradley, D. M., Cardullo, F., Marshall, H., Marzorati, P., Pozzan, A. and Ward, S. 2010. Compounds which potentiate the ampa receptor and uses thereof in medicine. WO2010066658A1 [Patent].
- Coulton, S., Gilpin, M. and Ward, S. 2010. N- inden- 2 -yl- isopropylsulfonamides as ampa receptor potentiators. WO2010057865A1 [Patent].
- Ward, S., Bax, B. D. and Harries, M. 2010. Challenges for and current status of research into positive modulators of AMPA receptors. British Journal of Pharmacology 160(2), pp. 181-190. (10.1111/j.1476-5381.2010.00726.x)
- Ward, S. and Betheleme, N. 2010. Compounds which potentiate the ampa receptor and uses thereof in medicine. WO2010037760 [Patent].
- Heer, J. P., Norton, D. and Ward, S. 2010. Pyrazolo [1, 5-a] pyrimidine derivatives. WO2010007074A1 [Patent].
- Ward, S. and Watson, J. M. 2010. Recent advances in the discovery of selective and non-selective 5-HT1D receptor ligands. Current Topics in Medicinal Chemistry 10(5), pp. 479-492. (10.2174/156802610791111533)
- Ward, S. and Harries, M. 2010. Recent advances in the discovery of selective AMPA receptor positive allosteric modulators. Current Medicinal Chemistry 17(30), pp. 3503-3513. (10.2174/092986710792927840)
2009
- Thewlis, K. M. and Ward, S. 2009. Compounds which potentiate the ampa receptor and uses thereof in medicine. WO2009092712A1 [Patent].
- Thewlis, K. M. and Ward, S. 2009. Compounds which potentiate the ampa receptor and uses thereof in medicine. WO2009092713A1 [Patent].
- Bertheleme, N., Chan, W. N., Scott, J. S. and Ward, S. 2009. Compounds which potentiate the ampa receptor and uses thereof in medicine. WO2009080637A1 [Patent].
- Chan, W. N., Harrison, S., Hughes, O. R., Neesom, J. K., Thewlis, K. M. and Ward, S. 2009. Compounds which potentiate ampa receptor and uses thereof in medicine. WO2009053448A1 [Patent].
- Chan, W. N., Thewlis, K. M. and Ward, S. 2009. Thiazoles which potentiate ampa receptor and medicinal uses thereof. WO2009053449A1 [Patent].
- Alderton, W., Karran, E. and Ward, S. 2009. Current and future perspectives in psychiatric drug discovery. Presented at: Society for Medicines Research Symposium, GlaxoSmithKline, Harlow, U.K, 12 March 2009, Vol. 22. Vol. 6. Thomson Reuters pp. 360-364., (10.1358/dnp.2009.22.6.1380328)
2008
- Ward, S. et al. 2008. Studies on a series of potent, orally bioavailable, 5-HT1 receptor ligands-Part II. Biorganic and Medicinal Chemistry Letters 19(2), pp. 428-432. (10.1016/j.bmcl.2008.11.052)
- Bartheleme, N. et al. 2008. Compounds which potentiate AMPA receptor and uses thereof in medicine. WO2008113795 [Patent].
- Bradley, D., Chan, W. N., Harrison, S., Thewlis, K. and Ward, S. 2008. Compounds which potentiate ampa receptor and uses thereof in medicine. WO2008110566A1 [Patent].
- Bradley, D., Thewlis, K. and Ward, S. 2008. Compounds which potentiate ampa receptor and uses therof in medicine. WO2008148832A1 [Patent].
- Bradley, D., Chan, W. N., Thewlis, K. and Ward, S. 2008. Compounds which potentiate ampa receptor and uses thereof in medicine. WO2008053031A1 [Patent].
- Ward, S. et al. 2008. Discovery of potent, orally bioavailable, selective 5-HT1A/B/DReceptor antagonists. Journal of Medicinal Chemistry 51(10), pp. 2887-2890. (10.1021/jm8001444)
- Gillespie, R. J. et al. 2008. Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives. Biorganic and Medicinal Chemistry Letters 18(9), pp. 2916-2919. (10.1016/j.bmcl.2008.03.075)
2007
- Bradley, D. et al. 2007. Compounds which potentiate ampa receptor and uses thereof in medicine. WO2007122241A1 [Patent].
- Bradley, D., Chan, W. N., Harrison, S., Thatcher, R., Thewlis, K. and Ward, S. 2007. Compounds which potentiate ampa receptor and uses thereof in medicine. WO2007107539A1 [Patent].
- Thewlis, K. and Ward, S. 2007. 4-phenyl-3-(2-propylsulfonylamino) tetrahydrofuran derivatives which potentiate glutamate receptors and are useful in the treatment of schizophrenia. WO2007090840A1 [Patent].
- Andreotti, D. and Ward, S. 2007. Compounds which potentiate glutamate receptor and uses thereof in medicine. WO2007090841A1 [Patent].
- Ward, S. et al. 2007. Studies on a series of potent, orally bioavailable, 5-HT1 receptor ligands. Biorganic and Medicinal Chemistry Letters 17(18), pp. 5214-5217. (10.1016/j.bmcl.2007.06.078)
- Ahmad, N. M., Rodeschini, V., Simpkins, N. S., Ward, S. and Blake, A. J. 2007. Synthesis of polyprenylated acylphloroglucinols using bridgehead lithiation: the total synthesis of racemic clusianone and a formal synthesis of racemic garsubellin A. The Journal of Organic Chemistry 72(13), pp. 4803-4815. (10.1021/jo070388h)
- Ahmad, N. M., Rodeschini, V., Simpkins, N. S., Ward, S. and Wilson, C. 2007. Synthetic studies towards garsubellin A: synthesis of model systems and potential mimics by regioselective lithiation of bicyclo[3.3.1]nonane-2,4,9-trione derivatives from catechinic acid. Organic & Biomolecular Chemistry 5(12), pp. 1924-1934. (10.1039/b704311b)
2006
- Craig, D., Hyland, C. J. T. and Ward, S. 2006. Stereoselective synthesis of (-)-trachelanthamidine (IV) via palladium-catalyzed intramolecular allylation.. Chem Inform 37(50) (10.1002/chin.200650213)
- Lovell, P. J. et al. 2006. 3,4-Dihydro-2H-benzoxazinones as dual-acting 5-HT1A receptor antagonists and serotonin reuptake inhibitors. Bioorganic and Medicinal Chemistry Letters 17(4), pp. 1033-1036. (10.1016/j.bmcl.2006.11.031)
- Bradley, D. et al. 2006. Acylated piperidihes as glycine transporter inhibitors. WO2006094842 [Patent].
- Andreotti, D., Arista, L., Cardullo, F., Spada, S., Thewlis, K. and Ward, S. 2006. Compounds which potentiate glutamate receptor and uses thereof in medicine. WO2006087169A1 [Patent].
- Bradley, D. et al. 2006. Glycine transport inhibitors. WO2006067423A1 [Patent].
- Bradley, D. et al. 2006. Glycine transport inhibitors. WO2006067417A1 [Patent].
- Thewlis, K. M. and Ward, S. 2006. Compounds which potentiate glutamate receptor and uses thereof in medicine. WO 2006015827 [Patent].
- Bradley, D. M., Thewlis, K. M. and Ward, S. 2006. Compounds which potentiate glutamate receptor and uses thereof in medicine. WO 2006015828 [Patent].
- Ward, S. and Thewlis, K. M. 2006. Compounds which potentiate glutamate receptor and uses thereof in medicine. WO2006015829 [Patent].
2005
- Craig, D., Hyland, C. J. T. and Ward, S. 2005. Stereoselective γ-lactam synthesis via palladium-catalysed intramolecular allylation. Chemical Communications- Royal Society of Chemistry(27), pp. 3439-3441. (10.1039/b504731e)
- Ward, S., Harrington, F. P., Gordon, L. J., Hopley, S. C., Scott, C. M. and Watson, J. M. 2005. Discovery of the first potent, selective 5-Hydroxytryptamine1D receptor antagonist [Letter]. Journal of Medicinal Chemistry 48(10), pp. 3478-3480. (10.1021/jm049039v)
- Bergauer, M. et al. 2005. Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors. WO 2005014552 [Patent].
2004
- Vong, A. and Ward, S. E. 2004. Benzoxazinone derivatives having affinity for 5- ht receptors, their preparation and use. WO 2004099198 [Patent].
- Vong, A. and Ward, S. E. 2004. Benzoxazinone derivatives, their preparation and use. WO2004099196A1 [Patent].
2003
- Harrington, F. P., Smith, P. W. and Ward, S. E. 2003. Heterocyclic compounds possessing affinity at 5ht1-type receptors and use thereof in therapy. WO2003068772A1 [Patent].
- Ward, S. E. 2003. Heterocyclymethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors. WO2003068771A1 [Patent].
- Smith, P. W., Thewlis, K. M., Vong, A. K. and Ward, S. E. 2003. Compounds possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders. WO2003068760A2 [Patent].
- Flynn, S. T., Smith, P. W., Thewlis, K. M., Ward, S. E. and Wyman, P. A. 2003. Piperidine and piperazine derivatives possessing affinity at 5ht-1 type receptors. WO2003068236A1 [Patent].
2000
- Gillespie, R. J., Monck, N. J., Bird, A. J. and Ward, S. E. 2000. 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission. WO2000044371A1 [Patent].
- Gillespie, R. J., Lerpiniere, J., Gaur, S., Adams, D. R., Knutsen, L. J. and Ward, S. E. 2000. 4-quinolinemethanol derivatives as purine receptor antagonists (i). WO2000013681A2 [Patent].
1999
- Gillespie, R. J., Snape, M. F. and Ward, S. E. 1999. 1-(adamantyl)amidines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission. WO1999031051A1 [Patent].
1998
- Adger, B. M., Dyer, U. C., Lennon, I. C., Tiffin, P. D. and Ward, S. 1998. A novel synthesis of tert-leucine via a Leuckart type reaction. Tetrahedron Letters 38(12), pp. 2153-2154. (10.1016/S0040-4039(97)00269-4)
1997
- Ward, S., Holmes, A. B. and McCague, R. 1997. Total synthesis of carbocyclic nikkomycin C. Chemical Communications- Royal Society of Chemistry(21), pp. 2085-2086. (10.1039/a705825j)
1993
- Congreve, M. S., Davison, E. C., Fuhry, M. A. M., Holmes, A. B., Payne, A. N., Robinson, R. A. and Ward, S. 1993. Selective cleavage of benzyl ethers [Letter]. Synlett 1993(9), pp. 663-664. (10.1055/s-1993-22563)
0
- Davis, A. M. and Ward, S. . The handbook of medicinal chemistry principles and practice. Cambridge: Royal Society of Chemistry.
- Ward, S. . AMPA receptor positive allosteric modulators a case history.. In: Cox, B. and Gosling, M. eds. Ion Channel Drug Discovery., Vol. 39. RSC Drug Discovery Series Vol. 39. Cambridge: Royal Society of Chemistry, pp. 105-134.
- Ward, S. . DNA damage repair pathways and synthetic lethality. In: Lackey, K. and Roth, B. eds. Medicinal Chemistry Approaches to Personalized Medicine., Vol. 59. Wiley-Blackwell, pp. 183-210.
- Ward, S. . Neurotransmitters and other non-opiate central mechanisms. In: Allerton, C. ed. Pain Therapeutics: Current and Future Paradigms. RSC Drug Discovery Series Vol. 35. Cambridge: Royal Society of Chemistry, pp. 171-196.
- Ward, S. . Discovery and clinical data for a novel AMPA receptor positive modulator. In: Rankovic, Z., Hargreaves, R. and Bingham, M. eds. Drug Discovery for Psychiatric Disorders. RSC Drug Discovery Series Vol. 28. Cambridge: Royal Society of Chemistry, pp. 99-122., (10.1039/9781849734943)
Articles
- Reeks, J. et al. 2025. High throughput cryo-EM provides structural understanding for modulators of the lysosomal ion channel TRPML1. Structure (10.1016/j.str.2025.05.014)
- Baldwin, A. G. et al. 2025. Discovery of MDI-114215: A potent and selective LIMK inhibitor to treat fragile X syndrome. Journal of Medicinal Chemistry 68(1), pp. 719-752. (10.1021/acs.jmedchem.4c02694)
- Baldwin, A. et al. 2025. Discovery of MDI-114215: A potent and selective LIMK inhibitor to treat Fragile X Syndrome. Journal of Medicinal Chemistry 68(1), pp. 719-752. (10.1021/acs.jmedchem.4c02694)
- Nicholls, R. A. et al. 2025. How do gepotidacin and zoliflodacin stabilize DNA-cleavage complexes with bacterial type IIA topoisomerases? 2. A single moving metal mechanism. International Journal of Molecular Sciences 26(1), article number: 33. (10.3390/ijms26010033)
- Cubitt, J. et al. 2024. Beware of N-Benzoyloxybenzamides. Molecules 29(21), article number: 5143. (10.3390/molecules29215143)
- Morgan, H. et al. 2024. How do Gepotidacin and Zoliflodacin stabilize DNA cleavage complexes with bacterial Type IIA topoisomerases? 1. Experimental definition of metal binding sites. International Journal of Molecular Sciences 25(21), article number: 11688. (10.3390/ijms252111688)
- Henderson, S. et al. 2024. Imidazo[1,2-b]pyridazines as inhibitors of DYRK kinases. European Journal of Medicinal Chemistry 269, article number: 16292. (10.1016/j.ejmech.2024.116292)
- Zhou, J. et al. 2023. Myeloid-intrinsic cell cycle-related kinase drives immunosuppression to promote tumorigenesis. iScience 26(10), article number: 107626. (10.1016/j.isci.2023.107626)
- Derudas, M. et al. 2023. Charge and lipophilicity are required for effective block of the hair-cell mechano-electrical transducer channel by FM1-43 and its derivatives. Frontiers in Cell and Developmental Biology 11, article number: 1247324. (10.3389/fcell.2023.1247324)
- Thomas, B., Lewis, L., Jones, D. and Ward, S. 2023. Central nervous system targeted protein degraders. Biomolecules 13(8), article number: 1164. (10.3390/biom13081164)
- Collins, R. et al. 2022. Comparative analysis of small-molecule limk1/2 inhibitors: chemical synthesis, biochemistry, and cellular activity. Journal of Medicinal Chemistry (10.1021/acs.jmedchem.2c00751)
- Koulouris, C. R. et al. 2022. Tyrosine 121 moves revealing a ligandable pocket that couples catalysis to ATP-binding in serine racemase. Communications Biology 5(1), article number: 346. (10.1038/s42003-022-03264-5)
- Scott, F. et al. 2022. Development of dihydropyrrolopyridinone-based PKN2/PRK2 chemical tools to enable drug discovery. Bioorganic and Medicinal Chemistry Letters 60, article number: 128588. (10.1016/j.bmcl.2022.128588)
- Henderson, S. H. et al. 2021. Discovery and characterization of selective and ligand-efficient DYRK inhibitors. Journal of Medicinal Chemistry 64(15), pp. 11709–11728. (10.1021/acs.jmedchem.1c01115)
- Zeng, X., Ward, S. E., Zhou, J. and Cheng, A. S. L. 2021. Liver immune microenvironment and metastasis from colorectal cancer-pathogenesis and therapeutic perspectives. Cancers 13(10), article number: 2418. (10.3390/cancers13102418)
- Kenyon, E. J. et al. 2021. Identification of a series of hair-cell MET channel blockers that protect against aminoglycoside-induced ototoxicity. JCI Insight 6(7), article number: e145704. (10.1172/jci.insight.145704)
- Cockerill, G. S. et al. 2021. Discovery of sisunatovir (RV521), an inhibitor of respiratory syncytial virus fusion. Journal of Medicinal Chemistry 64(7), pp. 3658-3676. (10.1021/acs.jmedchem.0c01882)
- Chen, X. et al. 2021. Uncovering an allosteric mode of action for a selective inhibitor of human Bloom syndrome protein. eLife 10, article number: e65339. (10.7554/eLife.65339)
- Henderson, S. H. et al. 2020. Mining public domain data to develop selective DYRK1A inhibitors. ACS Medicinal Chemistry Letters 11, pp. 1620-1626. (10.1021/acsmedchemlett.0c00279)
- Milton-Harris, L., Jeeves, M., Walker, S. A., Ward, S. E. and Mancini, E. J. 2020. Small molecule inhibits T-cell acute lymphoblastic leukaemia oncogenic interaction through conformational modulation of LMO2. Oncotarget 11(19), pp. 1737-1748. (10.18632/oncotarget.27580)
- Scott, F., Fala, A. M., Pennicott, L. E., Reuillon, T. D., Massirer, K. B., Elkins, J. M. and Ward, S. E. 2020. Development of 2-(4-pyridyl)-benzimidazoles as PKN2 chemical tools to probe cancer. Bioorganic and Medicinal Chemistry Letters 30(8), article number: 127040. (10.1016/j.bmcl.2020.127040)
- Maramai, S., Benchekroun, M., Ward, S. E. and Atack, J. R. 2020. Subtype selective y-Aminobutyric acid type A receptor (GABAAR) modulators acting at the benzodiazepine binding site: An update. Journal of Medicinal Chemistry 63(7), pp. 3425-3446. (10.1021/acs.jmedchem.9b01312)
- Ward, S. E. et al. 2020. Pharmacological characterisation of MDI-222, a novel AMPA receptor positive allosteric modulator with an improved safety profile. Journal of Psychopharmacology 34(1), pp. 93-102. (10.1177/0269881119872198)
- O'Reilly, M. et al. 2019. Design, synthesis, and biological evaluation of a new series of carvedilol derivatives that protect sensory hair cells from aminoglycoside-induced damage by blocking the mechanoelectrical transducer channel. Journal of Medicinal Chemistry 62(11), pp. 5312-5329. (10.1021/acs.jmedchem.8b01325)
- Mok, M. S., Zhou, J., Tang, W., Zeng, X., Oliver, A., Ward, S. and Cheng, A. S. 2018. CCRK is a novel signalling hub exploitable in cancer immunotherapy. Pharmacology & Therapeutics 186, pp. 138-151. (10.1016/j.pharmthera.2018.01.008)
- Henderson, S. H., West, R. A., Ward, S. E. and Honey, M. A. 2018. Metal-free selective mono-halodecarboxylation of heteroarenes under mild conditions. Royal Society Open Science 5(6), article number: 180333. (10.1098/rsos.180333)
- West, R. A., Cunningham, T., Pennicott, L. E., Rao, S. P. S. and Ward, S. 2018. Toward more drug like inhibitors of trypanosome alternative oxidase. ACS Infectious Diseases 4(4), pp. 592-604., article number: 7b00218. (10.1021/acsinfecdis.7b00218)
- Kenyon, E. J. et al. 2017. Identification of ion-channel modulators that protect against aminoglycoside-induced hair cell death. JCI Insight 2(24), article number: e96773. (10.1172/jci.insight.96773)
- West, R. A. et al. 2017. African trypanosomiasis: Synthesis & SAR enabling novel drug discovery of ubiquinol mimics for trypanosome alternative oxidase. European Journal of Medicinal Chemistry 141, pp. 676-689. (10.1016/j.ejmech.2017.09.067)
- Kirkwood, N. K. et al. 2017. d-Tubocurarine and berbamine: alkaloids that are permeant blockers of the hair cell's mechano-electrical transducer channel and protect from aminoglycoside toxicity. Frontiers in Cellular Neuroscience 11, article number: 262. (10.3389/fncel.2017.00262)
- Ward, S. et al. 2017. Pharmacological characterization of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2, 3-dihydro-1H-inden-2-yl]-2-propanesulfonamide: a novel, clinical AMPA receptor positive allosteric modulator. British Journal of Pharmacology 174(5), pp. 370-385. (10.1111/bph.13696)
- Meisenberg, C. et al. 2017. Epigenetic changes in histone acetylation underpin resistance to the topoisomerase I inhibitor irinotecan. Nucleic Acids Research 45(3), pp. 1159-1176. (10.1093/nar/gkw1026)
- Phuangsawai, O. et al. 2016. Evaluation of the anti-malarial activity and cytotoxicity of 2,4-diamino-pyrimidine-based kinase inhibitors. European Journal of Medicinal Chemistry 124, pp. 896-905. (10.1016/j.ejmech.2016.08.055)
- Ocasio, C. A. et al. 2016. A first generation inhibitor of human Greatwall kinase, enabled by structural and functional characterisation of a minimal kinase domain construct. Oncotarget 7(44), pp. 71182-71197. (10.18632/oncotarget.11511)
- Hornyak, P. et al. 2016. Mode of action of DNA-competitive small molecule inhibitors of tyrosyl DNA phosphodiesterase 2. Biochemical Journal 473(13), pp. 1869-1879. (10.1042/BCJ20160180)
- Moore, T. O., Paradowski, M. and Ward, S. 2016. An atom-efficient and convergent approach to the preparation of NS5A inhibitors by C-H activation. Organic and Biomolecular Chemistry 14(12), pp. 3307-3313. (10.1039/C6OB00340K)
- Reuillon, T., Ward, S. and Beswick, P. 2016. AMPA receptor positive allosteric modulators: Potential for the treatment of neuropsychiatric and neurological disorders. Current Topics in Medicinal Chemistry 16(29), pp. 3536-3565. (10.2174/1568026616666160627114507)
- Ward, S., Pennicott, L. E. and Beswick, P. 2015. AMPA receptor-positive allosteric modulators for the treatment of schizophrenia: an overview of recent patent applications. Future Medicinal Chemistry 7(4), pp. 473-491. (10.4155/fmc.15.4)
- Pearl, L. H., Schierz, A. C., Ward, S., Al-Lazikani, B. and Pearl, F. M. G. 2015. Therapeutic opportunities within the DNA damage response. Nature Reviews Cancer 15(3), pp. 166-180. (10.1038/nrc3891)
- Meisenberg, C., Gilbert, D. C., Chalmers, A., Haley, V., Gollins, S., Ward, S. and El-Khamisy, S. F. 2014. Clinical and cellular Roles for TDP1 and TOP1 in modulating colorectal cancer response to irinotecan. Molecular Cancer Therapeutics 14(2), pp. 575-585. (10.1158/1535-7163.MCT-14-0762)
- Meisenberg, C., Ward, S., Schmid, P. and El-Khamisy, S. F. 2014. TDP1/TOP1 Ratio as a Promising Indicator for the Response of Small Cell Lung Cancer to Topotecan. Journal of Cancer Science & Therapy 6(7), pp. 258-267. (10.4172/1948-5956.1000280)
- Ward, S. and Beswick, P. 2014. What does the aromatic ring number mean for drug design?. Expert Opinion on Drug Discovery 9(9), pp. 995-1003. (10.1517/17460441.2014.932346)
- Walker, S. et al. 2014. Development of an oligonucleotide-based fluorescence assay for the identification of tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors. Analytical Biochemistry 454, pp. 17-22. (10.1016/j.ab.2014.03.004)
- Ward, S. 2013. Targets and emerging therapies for schizophrenia. Edited by Jeffrey S. Albert and Michael W. Wood [Book Review]. ChemMedChem 8(3), pp. 529. (10.1002/cmdc.201200589)
- Ward, S. et al. 2011. Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators. Journal of Medicinal Chemistry 54(1), pp. 78-94. (10.1021/jm100679e)
- Leslie, C. P. et al. 2010. Discovery of 1-(3-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a potent, selective, and orally active 5-HT1A/B/DReceptor antagonist. Journal of Medicinal Chemistry 53(23), pp. 8228-8240. (10.1021/jm100714c)
- Thewlis, K. M., Aldegheri, L., Harries, M. H., Mookherjee, C., Oliosi, B. and Ward, S. 2010. N-Substituted pyrrolidines and tetrahydrofurans as novel AMPAR positive modulators. Bioorganic & Medicinal Chemistry Letters 20(23), pp. 7116-7119. (10.1016/j.bmcl.2010.09.062)
- Ward, S. et al. 2010. Discovery of N-[(2S)-5-(6-Fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator. Journal of Medicinal Chemistry 53(15), pp. 5801-5812. (10.1021/jm1005429)
- Ward, S., Bax, B. D. and Harries, M. 2010. Challenges for and current status of research into positive modulators of AMPA receptors. British Journal of Pharmacology 160(2), pp. 181-190. (10.1111/j.1476-5381.2010.00726.x)
- Ward, S. and Watson, J. M. 2010. Recent advances in the discovery of selective and non-selective 5-HT1D receptor ligands. Current Topics in Medicinal Chemistry 10(5), pp. 479-492. (10.2174/156802610791111533)
- Ward, S. and Harries, M. 2010. Recent advances in the discovery of selective AMPA receptor positive allosteric modulators. Current Medicinal Chemistry 17(30), pp. 3503-3513. (10.2174/092986710792927840)
- Ward, S. et al. 2008. Studies on a series of potent, orally bioavailable, 5-HT1 receptor ligands-Part II. Biorganic and Medicinal Chemistry Letters 19(2), pp. 428-432. (10.1016/j.bmcl.2008.11.052)
- Ward, S. et al. 2008. Discovery of potent, orally bioavailable, selective 5-HT1A/B/DReceptor antagonists. Journal of Medicinal Chemistry 51(10), pp. 2887-2890. (10.1021/jm8001444)
- Gillespie, R. J. et al. 2008. Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives. Biorganic and Medicinal Chemistry Letters 18(9), pp. 2916-2919. (10.1016/j.bmcl.2008.03.075)
- Ward, S. et al. 2007. Studies on a series of potent, orally bioavailable, 5-HT1 receptor ligands. Biorganic and Medicinal Chemistry Letters 17(18), pp. 5214-5217. (10.1016/j.bmcl.2007.06.078)
- Ahmad, N. M., Rodeschini, V., Simpkins, N. S., Ward, S. and Blake, A. J. 2007. Synthesis of polyprenylated acylphloroglucinols using bridgehead lithiation: the total synthesis of racemic clusianone and a formal synthesis of racemic garsubellin A. The Journal of Organic Chemistry 72(13), pp. 4803-4815. (10.1021/jo070388h)
- Ahmad, N. M., Rodeschini, V., Simpkins, N. S., Ward, S. and Wilson, C. 2007. Synthetic studies towards garsubellin A: synthesis of model systems and potential mimics by regioselective lithiation of bicyclo[3.3.1]nonane-2,4,9-trione derivatives from catechinic acid. Organic & Biomolecular Chemistry 5(12), pp. 1924-1934. (10.1039/b704311b)
- Craig, D., Hyland, C. J. T. and Ward, S. 2006. Stereoselective synthesis of (-)-trachelanthamidine (IV) via palladium-catalyzed intramolecular allylation.. Chem Inform 37(50) (10.1002/chin.200650213)
- Lovell, P. J. et al. 2006. 3,4-Dihydro-2H-benzoxazinones as dual-acting 5-HT1A receptor antagonists and serotonin reuptake inhibitors. Bioorganic and Medicinal Chemistry Letters 17(4), pp. 1033-1036. (10.1016/j.bmcl.2006.11.031)
- Craig, D., Hyland, C. J. T. and Ward, S. 2005. Stereoselective γ-lactam synthesis via palladium-catalysed intramolecular allylation. Chemical Communications- Royal Society of Chemistry(27), pp. 3439-3441. (10.1039/b504731e)
- Ward, S., Harrington, F. P., Gordon, L. J., Hopley, S. C., Scott, C. M. and Watson, J. M. 2005. Discovery of the first potent, selective 5-Hydroxytryptamine1D receptor antagonist [Letter]. Journal of Medicinal Chemistry 48(10), pp. 3478-3480. (10.1021/jm049039v)
- Adger, B. M., Dyer, U. C., Lennon, I. C., Tiffin, P. D. and Ward, S. 1998. A novel synthesis of tert-leucine via a Leuckart type reaction. Tetrahedron Letters 38(12), pp. 2153-2154. (10.1016/S0040-4039(97)00269-4)
- Ward, S., Holmes, A. B. and McCague, R. 1997. Total synthesis of carbocyclic nikkomycin C. Chemical Communications- Royal Society of Chemistry(21), pp. 2085-2086. (10.1039/a705825j)
- Congreve, M. S., Davison, E. C., Fuhry, M. A. M., Holmes, A. B., Payne, A. N., Robinson, R. A. and Ward, S. 1993. Selective cleavage of benzyl ethers [Letter]. Synlett 1993(9), pp. 663-664. (10.1055/s-1993-22563)
Book sections
- Ward, S. E. and Davis, A. M. 2023. Lead optimisation: what you should know!. In: Ward, S. E. and Davis, A. eds. The Handbook of Medicinal Chemistry: Principles and Practice. The Royal Society of Chemistry, pp. 720-768., (10.1039/9781788018982-00720)
- Ward, S. . AMPA receptor positive allosteric modulators a case history.. In: Cox, B. and Gosling, M. eds. Ion Channel Drug Discovery., Vol. 39. RSC Drug Discovery Series Vol. 39. Cambridge: Royal Society of Chemistry, pp. 105-134.
- Ward, S. . DNA damage repair pathways and synthetic lethality. In: Lackey, K. and Roth, B. eds. Medicinal Chemistry Approaches to Personalized Medicine., Vol. 59. Wiley-Blackwell, pp. 183-210.
- Ward, S. . Neurotransmitters and other non-opiate central mechanisms. In: Allerton, C. ed. Pain Therapeutics: Current and Future Paradigms. RSC Drug Discovery Series Vol. 35. Cambridge: Royal Society of Chemistry, pp. 171-196.
- Ward, S. . Discovery and clinical data for a novel AMPA receptor positive modulator. In: Rankovic, Z., Hargreaves, R. and Bingham, M. eds. Drug Discovery for Psychiatric Disorders. RSC Drug Discovery Series Vol. 28. Cambridge: Royal Society of Chemistry, pp. 99-122., (10.1039/9781849734943)
Books
- Davis, A. M. and Ward, S. . The handbook of medicinal chemistry principles and practice. Cambridge: Royal Society of Chemistry.
Conferences
- Ward, S., Dawson, L. A., Konneh, M. and MacDonald, G. 2016. Alzheimer's disease therapeutics - Are we making progress towards a disease-modifying treatment for patients? Highlights from the Society for Medicines Research Symposium, held June 20, 2016. Presented at: Society for Medicines Research Symposium, 20th June 2016, Vol. 41. Vol. 7. Prous Science pp. 461., (10.1358/dof.2016.041.07.2516439)
- Brown, K., Davenport, R. and Ward, S. 2015. Effective and emerging strategies for utilizing structure in drug discovery. Presented at: Society for Medicines Research Meeting, 19th March 2015, Vol. 40. Vol. 4. Prous Science pp. 251-256., (10.1358/dof.2015.040.04.2314768)
- Davenport, R., Armour, R. and Ward, S. 2011. Trends in pain research. Presented at: The Society for Medicines Research Pain Meeting, Girton College, Cambridge, UK, 24 March 2011, Vol. 36. Vol. 12. Prous Science pp. 943-948., (10.1358/dof.2011.036.12.1738058)
- Cowley, P., Hales, N. and Ward, S. 2011. Trends in medicinal chemistry. Presented at: The Society For Medicines Resarch Symposiun, NHLI, London, UK, 9 December 2010, Vol. 36. Vol. 7. Prous Science pp. 543-549., (10.1358/dof.2011.036.07.1622065)
- Alderton, W., Karran, E. and Ward, S. 2009. Current and future perspectives in psychiatric drug discovery. Presented at: Society for Medicines Research Symposium, GlaxoSmithKline, Harlow, U.K, 12 March 2009, Vol. 22. Vol. 6. Thomson Reuters pp. 360-364., (10.1358/dnp.2009.22.6.1380328)
Patents
- Ward, S. et al. 2022. Heteroaryl compounds useful in the treatment of cognitive disorders. WO2022/234271 [Patent].
- Cockerill, S., Mathews, N., Ward, S., Lunn, G., Paradowski, M. and Gascon Simorte, J. M. 2016. Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (RSV). WO2016055780A1 [Patent].
- Schindler, R. et al. 2016. Pyrazoles as NMDA NR2B receptor inhibitors and their preparation. WO2016025918A1 [Patent].
- Schindler, R., Lankau, H., Hofgen, N., Egerland, U., Langen, B., Dost, R. and Ward, S. 2016. Triazoles as nr2b receptor inhibitors. WO2016025917A1 [Patent].
- Gibbs, A. A., Ward, S. and Pennicott, L. E. 2013. Neurodevelopmental disorders. WO 2013/038200 A2 [Patent].
- Andreotti, D., Norton, D., Price, H. S., Profeta, R., Spada, S. and Ward, S. 2012. Piperazine derivatives as cav2.2 calcium channel blockers. WO2012098400A1 [Patent].
- Bertheleme, N., Beswick, P. J., Gleave, R. J., Hachisu, S., Vile, S. and Ward, S. 2012. Tetrazole compounds as calcium channel blockers. WO2012004604A1 [Patent].
- Bradley, D. M., Cardullo, F., Marshall, H., Marzorati, P., Pozzan, A. and Ward, S. 2010. Compounds which potentiate the ampa receptor and uses thereof in medicine. WO2010066658A1 [Patent].
- Coulton, S., Gilpin, M. and Ward, S. 2010. N- inden- 2 -yl- isopropylsulfonamides as ampa receptor potentiators. WO2010057865A1 [Patent].
- Ward, S. and Betheleme, N. 2010. Compounds which potentiate the ampa receptor and uses thereof in medicine. WO2010037760 [Patent].
- Heer, J. P., Norton, D. and Ward, S. 2010. Pyrazolo [1, 5-a] pyrimidine derivatives. WO2010007074A1 [Patent].
- Thewlis, K. M. and Ward, S. 2009. Compounds which potentiate the ampa receptor and uses thereof in medicine. WO2009092712A1 [Patent].
- Thewlis, K. M. and Ward, S. 2009. Compounds which potentiate the ampa receptor and uses thereof in medicine. WO2009092713A1 [Patent].
- Bertheleme, N., Chan, W. N., Scott, J. S. and Ward, S. 2009. Compounds which potentiate the ampa receptor and uses thereof in medicine. WO2009080637A1 [Patent].
- Chan, W. N., Harrison, S., Hughes, O. R., Neesom, J. K., Thewlis, K. M. and Ward, S. 2009. Compounds which potentiate ampa receptor and uses thereof in medicine. WO2009053448A1 [Patent].
- Chan, W. N., Thewlis, K. M. and Ward, S. 2009. Thiazoles which potentiate ampa receptor and medicinal uses thereof. WO2009053449A1 [Patent].
- Bartheleme, N. et al. 2008. Compounds which potentiate AMPA receptor and uses thereof in medicine. WO2008113795 [Patent].
- Bradley, D., Chan, W. N., Harrison, S., Thewlis, K. and Ward, S. 2008. Compounds which potentiate ampa receptor and uses thereof in medicine. WO2008110566A1 [Patent].
- Bradley, D., Thewlis, K. and Ward, S. 2008. Compounds which potentiate ampa receptor and uses therof in medicine. WO2008148832A1 [Patent].
- Bradley, D., Chan, W. N., Thewlis, K. and Ward, S. 2008. Compounds which potentiate ampa receptor and uses thereof in medicine. WO2008053031A1 [Patent].
- Bradley, D. et al. 2007. Compounds which potentiate ampa receptor and uses thereof in medicine. WO2007122241A1 [Patent].
- Bradley, D., Chan, W. N., Harrison, S., Thatcher, R., Thewlis, K. and Ward, S. 2007. Compounds which potentiate ampa receptor and uses thereof in medicine. WO2007107539A1 [Patent].
- Thewlis, K. and Ward, S. 2007. 4-phenyl-3-(2-propylsulfonylamino) tetrahydrofuran derivatives which potentiate glutamate receptors and are useful in the treatment of schizophrenia. WO2007090840A1 [Patent].
- Andreotti, D. and Ward, S. 2007. Compounds which potentiate glutamate receptor and uses thereof in medicine. WO2007090841A1 [Patent].
- Bradley, D. et al. 2006. Acylated piperidihes as glycine transporter inhibitors. WO2006094842 [Patent].
- Andreotti, D., Arista, L., Cardullo, F., Spada, S., Thewlis, K. and Ward, S. 2006. Compounds which potentiate glutamate receptor and uses thereof in medicine. WO2006087169A1 [Patent].
- Bradley, D. et al. 2006. Glycine transport inhibitors. WO2006067423A1 [Patent].
- Bradley, D. et al. 2006. Glycine transport inhibitors. WO2006067417A1 [Patent].
- Thewlis, K. M. and Ward, S. 2006. Compounds which potentiate glutamate receptor and uses thereof in medicine. WO 2006015827 [Patent].
- Bradley, D. M., Thewlis, K. M. and Ward, S. 2006. Compounds which potentiate glutamate receptor and uses thereof in medicine. WO 2006015828 [Patent].
- Ward, S. and Thewlis, K. M. 2006. Compounds which potentiate glutamate receptor and uses thereof in medicine. WO2006015829 [Patent].
- Bergauer, M. et al. 2005. Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors. WO 2005014552 [Patent].
- Vong, A. and Ward, S. E. 2004. Benzoxazinone derivatives having affinity for 5- ht receptors, their preparation and use. WO 2004099198 [Patent].
- Vong, A. and Ward, S. E. 2004. Benzoxazinone derivatives, their preparation and use. WO2004099196A1 [Patent].
- Harrington, F. P., Smith, P. W. and Ward, S. E. 2003. Heterocyclic compounds possessing affinity at 5ht1-type receptors and use thereof in therapy. WO2003068772A1 [Patent].
- Ward, S. E. 2003. Heterocyclymethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors. WO2003068771A1 [Patent].
- Smith, P. W., Thewlis, K. M., Vong, A. K. and Ward, S. E. 2003. Compounds possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders. WO2003068760A2 [Patent].
- Flynn, S. T., Smith, P. W., Thewlis, K. M., Ward, S. E. and Wyman, P. A. 2003. Piperidine and piperazine derivatives possessing affinity at 5ht-1 type receptors. WO2003068236A1 [Patent].
- Gillespie, R. J., Monck, N. J., Bird, A. J. and Ward, S. E. 2000. 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission. WO2000044371A1 [Patent].
- Gillespie, R. J., Lerpiniere, J., Gaur, S., Adams, D. R., Knutsen, L. J. and Ward, S. E. 2000. 4-quinolinemethanol derivatives as purine receptor antagonists (i). WO2000013681A2 [Patent].
- Gillespie, R. J., Snape, M. F. and Ward, S. E. 1999. 1-(adamantyl)amidines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission. WO1999031051A1 [Patent].
Ymchwil
Mae'r Athro Ward yn Ymchwilydd ar sawl dyfarniad grant, gan gynnwys y dyfarniadau canlynol:
|
Prosiectau Byw |
Cyllidwr |
Gwerth |
|
KAT2A PROTACs sy'n targedu gwahaniaethu ffrwydrau a bôn-gelloedd lewcemig ar gyfer trin Lewcemia Myeloid Acíwt [PI] |
Cartref |
>£1M |
|
Gwella swyddogaeth llinyn y cefn GlyRa3 fel dull newydd o drin poen [coI] |
Cartref |
>£1M |
|
Moleciwlau offeryn ar gyfer ataliad NEAT1 [PI] |
Coleg Cymraeg Cenedlaethol |
Ysgoloriaeth PhD |
|
Chimeras Targedu Protein (PROTACs) ar gyfer treiddiad CNS [PI] |
Fferyllol Janssen |
Ysgoloriaeth PhD |
|
Astudiaethau clinigol Cam 1 ar gyfer MDI-478: Modiwlydd allosterig positif derbynnydd AMPA ar gyfer trin nam gwybyddol sy'n gysylltiedig â sgitsoffrenia [PI] |
Ymddiriedolaeth Wellcome |
>£6M |
|
Modulators allosterig o dderbynyddion delta-GABAA allsynaptig ar gyfer trin iselder ôl-enedigol [coI] |
Cartref |
>£5M |
|
Dylunio a datblygu modulators derbynnydd AMPA gyda phroffil diogelwch llawer gwell fel cyffuriau newydd ar gyfer trin y camweithrediad gwybyddol sy'n gysylltiedig â sgitsoffrenia ac anhwylderau CNS eraill [PI] |
Ymddiriedolaeth Wellcome |
>£4M |
|
Prawf Cysyniad ar gyfer a5-GABAAR PAMs wrth drin seicosis [coI] |
Ymddiriedolaeth Wellcome |
>£500k |
|
Datblygu moleciwlau bach fel strategaeth amnewid niwrosteroidau ar gyfer trin seicosis ôl-enedigol [coI] |
Ymddiriedolaeth Wellcome |
>£500k |
|
Targedu proteinau Prion gyda PROTACs [PI] |
Coleg Cymraeg Cenedlaethol |
Ysgoloriaeth PhD |
|
Atal ceramidase asid i drin anhwylderau storio lysosomaidd lluosog [coI] |
Clefyd Prin Harrington |
£100k |
|
Modiwlyddion Derbynnydd α5-GABAA ar gyfer Trin Nam Gwybyddol sy'n Gysylltiedig â Chlefyd Huntington [coI] |
Ymddiriedolaeth Wellcome |
>£3M |
Bywgraffiad
Mae gan yr Athro Ward MA mewn Gwyddorau Naturiol a PhD mewn cemeg organig synthetig o Brifysgol Caergrawnt, y Deyrnas Unedig. Mae ganddo brofiad eang o ddarganfod cyffuriau mewn cwmnïau fferyllol, biotechnoleg ac academaidd mawr (GlaxoSmithKline, BioCrea GmbH, Knoll Pharmaceuticals, Vernalis, Ceirowyddoniaeth, Prifysgol Sussex, Prifysgol Caerdydd) a phrofiad arbenigol o ddatblygu meddyginiaethau newydd ar gyfer cleifion â salwch niwrolegol a seiciatrig ac yn erbyn canser. Yn 2010, ar ôl gyrfa ymchwil mewn diwydiant, cyfunodd yr Athro Ward rolau mewn cwmnïau biotechnoleg gyda rôl academaidd, sefydlu un o brif grwpiau darganfod cyffuriau prifysgolion y DU gan sicrhau dros £50 miliwn o gyllid academaidd gan gyllidwyr elusennol, y llywodraeth a diwydiannol.
Yn ogystal â rolau ymgynghori allanol a biotechnoleg, mae'r Athro Ward hefyd:
- Aelod o'r Pwyllgor Cynghori Gwyddonol Arbenigol, Medicines for Malaria Venture
- Aelod o'r Bwrdd Cynghori Gwyddonol, Sefydliad Therapiwteg Canser, Bradford, y DU
- Bwrdd Cynghori, Enterprise Therapeutics
- Aelod o Fwrdd Rheoli Arloesi Caerdydd, y DU
- Aelod o'r Bwrdd Cynghori ar gyfer cyfnodolion Bioorganic and Medicinal Chemistry & Bioorganic and Medicinal Chemistry Letters, Elsevier a Medicinal Chemistry Letters, American Chemical Society
- Cadeirydd Cwrs Hyfforddi Preswyl Cemeg Feddyginiaethol Cymdeithas Frenhinol Cemeg
- Cyd-olygydd The Handbook of Medicinal Chemistry: Principles and Practice, Cymdeithas Frenhinol Cemeg 2015 a 2023
- Cyd-brif olygydd Cemeg Feddyginiaethol Gynhwysfawr Cyfrol IV, Elsevier 2025
- Aelod o Sefydliad Panel Arbenigwyr Buddsoddi Ymchwil mewn Technolegau Iechyd Byd-eang (RIGHT), Korea
Mae'r Athro Ward yn Gymrawd o'r Gymdeithas Cemeg Frenhinol, yn Gemegydd Siartredig, ac yn Wyddonydd Siartredig (FRSC CChem CSci).
Contact Details
Themâu ymchwil
Arbenigeddau
- Datblygu cyffuriau
- Cemeg Feddyginiaethol
- Darganfod Cyffuriau
